Monday, April 30, 2012
FDA approves fast-acting Viagra rival, Stendra
Posted by Sex and Love editor on Mon, Apr 30, 2012 at 9:50 AM
Stendra's parent company, Vivus Inc., will compete with the three other ED medications on the US market: Viagra, Cialis, and Levitra. However, the new drug may have a leg up on the competition.
Clinical trials of Stendra showed that it started working in as little as 15 minutes, compared to an hour for Viagra.
While Stendra also works by increasing blood flow to the penis, the clinical trials suggest that Stendra is more selective. This specificity is expected to result in fewer side-effects.
With over 30 million men in the US suffering from some form of ED, it is anticipated that Stendra will pull in about $300 million in sales annually. In contrast, Viagra earned about $2 billion in 2011. Interestingly enough, a new erection medication may not be enough to arouse investors. Market analysts are more excited about the earning potential of Vivus's obesity drug, Qnexa, which will be reviewed by the FDA in July.
Read more at FoxNews.com
Follow Alfie on Twitter or Facebook and email him if interested in writing about Sex & Love
Comments (1)
Showing 1-1 of 1
Latest in Daily Loaf
-
Rick Kriseman says Kathleen Ford's advocacy against the Lens could hurt her run for mayor
Kriseman said city officials have made a mistake by opting to shut down the Pier next weekend.
-
Summertime farmers markets
There's no need to worry about a lack of local produce.
-
Rowdies win award at Soiree, advance to Cup
The Rowdies have been quite busy over the past couple of weeks, moving into a tie for first place and much more.
- More »
More by Sex and Love editor
-
The Bachelor
A work of literotica about what happens when a Miami stripper invites a reluctant bachelor back to her hotel.
-
Top 10 best condoms
Based on orders and online user ratings at CondomDepot.com.
- More »
